Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids
Authors:
- 12 May 2011
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 96 (9) , 1351-1356
Abstract
Advances in acute graft-versus-host disease therapy are needed. We examined the efficacy of sirolimus as primary therapy for acute graft-versus-host disease in 32 patients. Acute graft-versus-host disease involved the skin in 53% of cases, gastrointestinal tract in 66%, liver in 16%. The syndrome was overall grade 1 in 12% cases, grade 2 in 75%, and grade 3 in 13%. Sirolimus was targeted to achieve serum trough levels of 5-14 ng/mL. Sixteen (50%) patients achieved sustained, complete resolution of acute graft-versus-host disease with sirolimus alone. In contrast, 19 of 32 (59%) matched historical controls treated with standard 1 mg/kg steroids achieved complete response (P=0.47). With median follow-up time for surviving patients of 16 (range 6-26) months, one year overall survival was 56% (95% CI 38-74%). The cumulative incidence of relapse at one year was 37% (95% CI 23-60%), and mortality in remission was 20% (95% CI 10-42%). The cumulative incidence of chronic graft-versus-host disease was 55% (95% CI 39-79%). Thrombotic microangiopathy occurred in 3 cases (grade 1 n=1; grade 2 n=2), and responded to dose reduction of calcineurin inhibitor. In this retrospective series, sirolimus demonstrates activity comparable to that of high-dose glucocorticoids in the primary therapy of acute graft-versus-host disease. Confirmation of this activity requires prospective clinical trials.Keywords
This publication has 20 references indexed in Scilit:
- Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkBlood, 2009
- Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2009
- Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinomaCancer, 2009
- Targeting the mTOR Signaling Network for Cancer TherapyJournal of Clinical Oncology, 2009
- Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trialBlood, 2004
- Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantationBone Marrow Transplantation, 2002
- Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systemsTransplantation and Cellular Therapy, 2002
- Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow TransplantationJournal of Clinical Oncology, 2002
- Health and Functional Status of Long-Term Survivors of Bone Marrow TransplantationAnnals of Internal Medicine, 1997
- A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment.1991